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Abstract
Mathematical modelling has successfully been used to provide quantitative descriptions of
many viral infections, but for the Ebola virus, which requires biosafety level 4 facilities for
experimentation, modelling can play a crucial role. Ebola virus modelling efforts have pri-
marily focused on in vivo virus kinetics, e.g., in animal models, to aid the development of
antivirals and vaccines. But, thus far, these studies have not yielded a detailed specification
of the infection cycle, which could provide a foundational description of the virus kinetics and
thus a deeper understanding of their clinical manifestation. Here, we obtain a diverse experi-
mental data set of the Ebola virus infection in vitro, and then make use of Bayesian inference
methods to fully identify parameters in a mathematical model of the infection. Our results
provide insights into the distribution of time an infected cell spends in the eclipse phase (the
period between infection and the start of virus production), as well as the rate at which infec-
tious virions lose infectivity. We suggest how these results can be used in future models to
describe co-infection with defective interfering particles, which are an emerging alternative
therapeutic.
Author summary
The two deadliest Ebola virus epidemics have both occurred in the past five years, with
one of these epidemics still ongoing. Mathematical modelling has already provided
insights into the spread of disease at the population level as well as the effect of antiviral
therapy in Ebola virus-infected animals. However, a quantitative description of the
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replication cycle is still missing. Here, we report results from a set of in vitro experiments
involving infection with the Ecran strain of Ebola virus. By parameterizing a mathematical
model, we are able to determine robust estimates for the duration of the replication cycle,
the infectious burst size, and the viral clearance rate.
Introduction
The world’s second largest Ebola outbreak is currently underway in the Democratic Republic
of Congo. Ebola virus (EBOV) causes severe and fatal disease with death rates of up to 90% [1].
There is an urgent need to prevent and treat EBOV infections, but no antiviral drugs or mono-
clonal antibodies have been approved in Africa, the EU, or the US. Recently the first EBOV
vaccine has been approved by European regulators [2]. Experimental therapies [3], including
antiviral drugs (remdesivir [4] and favipiravir [5, 6]) and a cocktail of monoclonal antibodies
(ZMapp) [7], have been assessed in the 2013–2016 West Africa Ebola virus disease outbreak.
Other promising monoclonal antibody therapies, called mAb114 and REGN-EB3, have been
deployed in the current 2018–2019 Kivu Ebola virus epidemic [8]. A better understanding of
the precise infection kinetics of EBOV is warranted.
Mathematical modelling of viral dynamics has provided a quantitative understanding of
within-host viral infections, such as HIV [9], influenza [10], Zika [11], and more recently,
EBOV. Mathematical modelling studies have analyzed the plasma viral load dynamics of
EBOV-infected animals (mice [12], non-human primates [13, 14]) while under therapy with
favipiravir, and have identified estimates of favipiravir efficacy and target drug concentrations.
In addition, mechanistic models of innate and adaptive immune responses were used to pro-
vide an explanation of EBOV infection dynamics in non-human primates [14], and of differ-
ences between fatal and non-fatal cases of human infection [15]. Moreover, mathematical
models have been used to predict the effect of treatment initiation time on indicators of disease
severity [12, 15] and survival rates [14], to predict the clearance of EBOV from seminal fluid of
survivors [16], and to theoretically explore treatment of EBOV-infected humans with antivirals
that possess different mechanisms of action (i.e., nucleoside analog, siRNA, antibody) [15].
Alongside the progress made in understanding within-host infections, a complementary
view of infection can be provided by mathematical modelling of infections at the in vitro level.
Combined with in vitro time course data, mathematical models (MMs) have provided a
detailed quantitative description of the viral replication cycle of influenza A virus [17, 18],
SHIV [19, 20], HIV [21], and other viruses [22–26]. Such studies yield estimates of key quanti-
ties such as the basic reproductive number (defined as the number of secondary infections
caused by one infected cell in a population of fully susceptible cells), half-life of infected cells,
and viral burst size, which cannot be obtained directly from data [27]. In the context of in vitro
infections, parameterized MMs have been used to predict the outcome of competition experi-
ments between virus strains [28–30] (i.e., which strain dominates in a mixed infection), map
differences in genotype to changes in phenotype [28, 30] (e.g., associate a single mutation to
ten-fold faster viral production), quantify fitness differences between virus strains [31, 32]
(e.g., which strain has a larger infectious burst size), quantify the contribution of different
modes of transmission (cell-to-cell versus cell-free) [21], and identify the target of antiviral
candidates [33] (e.g., whether a drug inhibits viral entry or viral production). One prior study
[34] utilized in vitro infection data from the literature to estimate EBOV infection parameters,
but had several parameter identifiability issues due to insufficient data.
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Our goal is to obtain robust estimates of viral infection parameters that characterize the
EBOV replication cycle. We follow a mathematical modelling approach that has been success-
fully applied in the analysis of other viral infections in vitro [17]. To this end, we performed a
suite of in vitro infection assays (single-cycle, multiple-cycle, and viral infectivity decay assays)
using EBOV and Vero cells, and collected detailed extracellular infectious and total virus time
courses. The viral kinetic data were simulated with a multicompartment ordinary differential
equation MM, and posterior distributions of the MM parameters were estimated using a Mar-
kov chain Monte Carlo (MCMC) approach. We estimate that one EBOV-infected cell spends
�30 h in an eclipse phase before it releases infectious virions at a rate of 13/h, over its infec-
tious lifetime of�83 h. The number of infectious virions produced over an infected cell’s
lifetime is�1000, with an estimated basic reproductive number of�600. We also discuss chal-
lenges in collecting other types of virus dynamic data (e.g., intracellular viral RNA or cell
counts).
Results
Ebola virus kinetics in vitro
Vero cell monolayers were infected with EBOV at a multiplicity of infection (MOI) of 5, 1, 0.1
TCID50/cell. Infectious and total virus concentrations were determined from extracellular
virus harvested from the supernatant of each well at various times post-infection (Fig 1A–1C,
1E and 1F). At the start of infection, the virus concentrations do not rise for some time, reflect-
ing the time it takes for viral entry, replication and release. After 24 h, the virus concentrations
grow exponentially as infected cells begin producing virus. When all cells in the well are
Fig 1. Kinetics of EBOV infection in vitro and mock yield assays. Vero cell monolayers were infected with EBOV at a multiplicity of infection (MOI)
5, 1, or 0.1 TCID50/cell, as indicated. At various times post-infection, the infectious (TCID50/mL; A–C) and total virus (copy/mL; E–G) in the
supernatant were determined. A mock yield assay was also performed to quantify the decay of infectious (D) and total virus (G). In each assay, the
experimental data (circles) were collected either in duplicate (MOI 5) or triplicate (all other assays). Note that the total virus concentration collected in
the MOI 5 infection was omitted from the analysis due to inconsistencies in the peak value (S1 Appendix, Fig. A). The lines represent the pointwise
median of the time courses simulated from our MM, which are bracketed by 68% (light grey) and 95% (dark grey) credible regions (CR). These data
were used to extract the posterior probability likelihood distributions of the infection parameters (Fig 2). Note that parameters of the calibration curve
used to convert cycle threshold values (Ct) to total virus (copy/mL) were also estimated (Fig 3). The variability introduced from this conversion is
shown by two error bars on each total virus data point, indicating the 68% (same colour) and 95% (black) CR.
https://doi.org/10.1371/journal.pcbi.1008375.g001
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infected, the virus concentrations peak at approximately 2 × 107TCID50/mL and 1013 copy/mL
and the peak is sustained for�72 h. Thereafter, the virus concentrations decline when virus
production ceases, presumably due to the death of infected cells. Additionally, the kinetics of
viral infectivity decay and virus degradation were assessed with a mock yield assay (Fig 1D and
1G). In the mock yield assay, an inoculum of virus was incubated in wells under the same con-
ditions as the growth assays, but in the absence of cells, and sampled over time.
Mathematical model of viral infection and parameter estimates
The in vitro EBOV infection kinetics were captured with a MM that has been used successfully
in past works to capture influenza A virus infection kinetics in vitro [28, 30, 31]. The MM is












































In this MM, susceptible uninfected target cells T can be infected by infectious virus Vinf
with infection rate constant β, and subsequently enter the non-productive eclipse phase
Ei¼1;...;nE , followed by a transition into the productively infectious phase Ij¼1;...;nI . The eclipse and
infectious phases are divided into a number of compartments given by nE and nI, respectively,




p . While cells are in the infectious phase, they produce infectious (total) virus Vinf
(Vtot) at a rate pinf (ptot), which lose infectivity (viability) at rate cinf (ctot). The MM Eq (1) cap-
tures both infectious virus, quantified by TCID50 measurements of supernatant samples, and
total virus, quantified by quantitative, real-time, reverse transcriptase PCR (hereafter, RT-
qPCR). The latter experimental quantity was obtained by converting cycle threshold (Ct) val-
ues from RT-qPCR to copy number (Fig 3) using Eq (3) (Methods).
Predicted virus time courses from the MM are shown in Fig 1 where the solid lines repre-
sent the pointwise median and the grey bands show narrow 95% credible regions (CR), indi-
cating that the MM reproduces the viral kinetic data well. Using a Markov chain Monte Carlo
(MCMC) approach, we obtained posterior probability likelihood distributions (PostPLDs) for
each of the MM parameters (Fig 2). Narrow PostPLDs were extracted with mild correlations
between parameters (S1 Appendix, Fig. C), indicating good practical identification of all
parameters.
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A quantitative description of the EBOV lifecycle
The MCMC analysis gives us the following quantitative description of the EBOV lifecycle
within Vero cells. An EBOV-infected Vero cell spends approximately 30 h with a 95%
credible region of [26 h, 37 h] in the eclipse phase before progeny EBOV successfully
bud. Subsequently, infectious virus is produced at a rate of 13 [10, 20] virions per cell per
hour over a duration of 83 h [64 h, 95 h] before virus production ceases due to cell death.
An infectious burst size of 1096 progeny virions [1000, 1259] is released from each infected
cell over its virus-producing lifetime. Once infectious virus enters the cell culture medium,
they lose infectivity at a rate of 0.06 /h [0.055 /h, 0.068 /h], which is comparable to other
viruses such as influenza A virus [31] or SHIV [19]. Overall, the in vitro spread of infection
is rapid, as characterized by an infecting time of 2 h [1.6 h, 2.7 h], which is defined as the
time required for a single virus-producing cell to infect one more [35]. These dynamics
imply a large basic reproductive number of 589 [398, 1000], which is defined as the number
of secondary infections caused by a single infected cell in a population of fully susceptible
cells.
Notably, we find that the durations of both the eclipse and infectious phases follow a nor-
mal-like distribution, as given by nE of 13 [8, 23] and nI of 14 [3, 85]. This implies that the
eclipse phase comprises a sequence of many distinct steps of short duration, without any one
step lasting significantly longer than the rest. Likewise, the same interpretation applies to the
infectious phase. The normal-like distribution of the eclipse phase resembles that of influenza
A virus [30], but contrasts with the fat-tailed eclipse phase distribution of SHIV [20] which is
likely due to a process in the phase that is longer than the rest (e.g., integration). Moreover,
neither the eclipse nor infectious phase are exponentially distributed (n = 1) as is commonly
assumed in analyses with MMs. Such an assumption has been shown to impact estimates of
antiviral efficacy that are based on patterns of viral load decay under simulated therapy in HIV
patients [20].
Fig 2. Estimated parameter distributions of EBOV infection in vitro. Posterior probability likelihood distributions (PostPLDs) of parameters in the
MM (A–G) were estimated using MCMC and the data in Fig 1. Secondary parameters were derived from these estimates (H–J). Note that the PostPLDs
corresponding to the number of eclipse and infectious phase compartments are integer-valued. The remaining PostPLDs of parameters describing the
total virus and calibration curve are in S1 Appendix, Fig. B.
https://doi.org/10.1371/journal.pcbi.1008375.g002
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Discussion
In this work we performed time-course Ebola virus (EBOV) infection experiments at multiple
MOIs in vitro and applied MCMC methods to precisely parameterize a mathematical model
(MM) of the infection. We extracted fundamental quantities concerning the timing and viral
production of EBOV replication. This theoretical-experimental approach maximized the out-
put of the costly and difficult experiments, which must be performed in biosafety level 4 facili-
ties. Previous studies of the EBOV lifecycle rely on safer virus-like particles [36]. The only
previously known MM of EBOV infection in vitro [34] is restricted in its use due to problems
with parameter identifiability; specifically, the existence of strong correlations between param-
eters, such as the rates of virus degradation and virus production. By obtaining a more com-
plete set of experimental observations, we have provided the first detailed quantitative
characterization of EBOV infection kinetics.
Some of our estimates of timescales in the EBOV infection kinetics fill gaps in the knowl-
edge of this virus, while others expose some tension with prior mathematical modelling
work. The eclipse phase, excluded from the previous in vitro MM [34], has been found to
be a significant part of the replication cycle. Lasting approximately 30 h, it is longer than
the eclipse phase for influenza A virus and HIV infections in humans (4–24 h) [10, 37].
Although the eclipse phase is included in existing MMs of EBOV-infected animals, its dura-
tion has never been estimated, and the assumed values used in these studies were consider-
ably shorter than the value we identify here [12, 14]. Moreover, the observation that the
length of the eclipse phase follows an Erlang distribution is contrary to these previous MMs,
where it has been represented more simply as an exponentially distributed time. These MMs
also fix the value of the decay rate of infectious virus to ensure that other parameters remain
identifiable [12]. Here, the robust estimate of this decay rate demonstrates the benefit of per-
forming a mock yield assay. Existing MMs of in vivo EBOV infection in humans and non-
human primates provide considerably shorter estimates of the infection cycle (12.5–15.3 h)
compared to the estimate of 114 h (τE + τI) obtained here [12, 15]. Such a difference is likely
attributed to the inclusion of an implicit immune response in these in vivo models, thereby
accounting for the enhanced clearance of infected cells by immune cells, such as CD8+ T
cells [38]. This also explains why a faster viral decay rate can be expected in vivo, and
subsequently why estimates of the basic reproduction number are greater here than those
obtained from in vivo MMs (5.96-9.01) [12, 15]. It remains to be determined whether Vero
cells are representative of the cells targeted by EBOV in vivo, but by understanding EBOV
replication in Vero cells, we have a foundation from which more complex cell culture mod-
els might be developed.
In addition to virus measurements, previous studies have included susceptible and infected
cell measurements to fully parameterize the MM and obtain robust estimates of the viral kinet-
ics parameters [19, 39]. We initially set out to obtain a more diverse data set that also included
the kinetics of dead cells and intracellular RNA over the course of infection, but encountered
unexpected challenges. To quantify cell viability, we treated infected monolayers at various
times with Trypan blue, which stains cells that have lost the ability to exclude dye. Unfortu-
nately, we were unable to associate this marker of cell death to a stage of the viral lifecycle in
our MM without making additional assumptions. Ultimately, when we extended the MM to
include these data, the newly introduced parameters were dependent on these assumptions,
and the extracted values of the original parameters were largely unaffected (S1 Appendix).
To determine intracellular viral kinetics, the supernatants from infected cell cultures were
removed and the remaining monolayers were washed and trypsinized for quantification via
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TCID50 assay and RT-qPCR. These samples showed a high level of EBOV RNA and TCID50 as
early as 4 hours post-infection, which remained at a constant level up to 1 day post-infection,
but rose thereafter (S1 Appendix). Additionally, the ratio of RNA-to-TCID50 resembled the
ratio observed in the supernatant. Thus, these measurements likely reflect the large amount of
cell-associated virions that remained after washing, effectively obscuring the intracellular RNA
signal.
While a highly-controlled in vitro system was necessary to achieve our precise characteriza-
tion of the EBOV infection kinetics, the applicability of these results to a clinical situation is
not immediately obvious, and represents a serious limitation of the study. Nevertheless, our
findings have some relevance to understanding the EBOV infection in vivo. EBOV initially
replicates within macrophages and dendritic cells in subcutaneous and submucosal compart-
ments, but dissemination in the blood results in the infection of multiple organs throughout
the body [40]. Many different cell types are infected with varying susceptibility to infection, as
well as varying levels of viral replication. While the infection unfolds, EBOV blocks IFN pro-
duction early on [6, 41]. In this sense, studying the infection of Vero cells—which are IFN-
deficient—narrowly models the infection of one type of epithelial cell during the early stages of
an EBOV infection in vivo.
Vero cells serve as a standard host cell for replication and are widely used for testing
antivirals in vitro [42], as well as in the development of viral vaccines [43–45]. Mathematical
modelling of EBOV infections in vitro using Vero cells has relevance to such applications, par-
ticularly in the study of emerging therapeutics. While we provided a quantitative depiction of
extracellular infection by EBOV as a valuable first step, we envisioned that the MM could be
extended to include intracellular viral RNA kinetics had the appropriate data been collected.
Such multiscale modelling approaches have been used to provide insight into virus growth and
also to the understanding of direct-acting antivirals [46–49]. We hope that these experiences
might help guide future efforts to obtain informative cell and intracellular data.
As an alternative antiviral strategy, there has been renewed interest in pursuing defective
interfering particles (DIPs) [50] of highly pathogenic viruses. A DIP is a viral particle that con-
tains defective interfering RNA (DI RNA), which can be a shortened version of the parent
genome that renders a DIP replication-incompetent on its own (because it may lack the gene
for an essential viral component such as viral polymerase), but also elicits virus-interfering
properties. Within a cell co-infected by both DIPs and virus, the DI RNA has a replicative
advantage over the full-length RNA and outcompetes it to produce more DIPs than virus prog-
eny, effectively reducing the infectious virus yield. EBOV DI RNA has been detected [51] but
much remains to be understood. Like with any other antiviral, MMs can be used to determine
the efficacy and mechanism of action of candidate DI RNAs, and to explore the impact of dose
and timing [15]. In particular, our estimates of EBOV infection kinetics parameters are directly
applicable to future mathematical modelling of the interactions between EBOV and EBOV
DIPs in vitro. Our estimated EBOV infection parameters may also describe certain aspects of
EBOV DIP infection. For example, since DIPs have the same viral proteins and capsid as viri-
ons, they would infect cells with the same infection rate constant, β. Since DIPs also piggyback
on the virus’ replication cycle, we might expect the same eclipse and infectious phase lengths
(τE, τI) in a DIP and virus co-infected cell.
In summary, the MM described here characterizes the replication cycle of EBOV in a quan-
titative manner that will be beneficial for those creating in vitro models to aid the development
of antivirals and vaccines. We have made use of a valuable set of in vitro results, carefully con-
sidering the structure of the MM in order to maximize the information we can extract from
them.
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Materials and methods
Cells and virus
Vero C1008 cells (ECACC Cat. No.85020206) were obtained from Culture Collection, Public
Health England, UK. Vero C1008 cells were maintained in Dulbecco’s minimum essential
media supplemented with 10% (v/v) foetal calf serum, 1% (v/v) L-glutamine and 1% (v/v) pen-
icillin/streptomycin (Sigma). For experimental purposes, the foetal calf serum concentration
was reduced to 2% (v/v).
Ebola virus H. sapiens-tc/COD/1976/Yambuku-Ecran, hereafter referred to as EBOV was
used in all studies. This virus, previously known as EBOV “E718” [52] was supplied by Public
Health England. Passage 5 material was used to infect Vero C1008 cells. Virus was harvested
on day 5 post-inoculation and titrated to produce a working stock at 107 TCID50/mL.
Quantification of virus
EBOV was titrated in 96-well plates using the endpoint fifty percent tissue culture infectious
dose (TCID50) assay [53]. Briefly, virus was ten-fold serially diluted in 96 well plates of Vero
C1008 cells. After one week of incubation at 37˚C/5% CO2, all wells were observed under the
microscope and scored for presence or absence of cytopathic effects. The 50% endpoint was
then calculated using the method of Reed & Muench [54]. RNA extractions were performed
using the QiAMP Viral RNA Mini Kit (Qiagen, UK). Two 50 μL elutions were performed for
each sample to increase the volume available for RT-PCR.
The genetic material of EBOV was quantified using the RealStar1 Filovirus Screen
RT-PCR Kit (Altona diagnostics, Country) following the instructions of the manufacturer.
This assay has been performed many times against a standard curve of plasmid containing
the L gene from EBOV. The number of genomes can be estimated from the Ct values as
described in Eq (3). In this context, the number of genomes might consist of incomplete neg-
ative sense RNA molecules encoding this sequence of the L gene. However, we do not believe
that these will be common (<5%) based upon observations made with next generation
sequencing (paper in preparation). MOI 5 experiments were analysed using a BIORAD CFX
Connect—Real Time System, while samples for the remaining MOIs were analysed using a
QuantStudio 7 Flex Real-Time PCR System. Signal from control RNA was compared
between experiments and machines and we found no evidence of differences. The parame-
ters of the calibration curve required to convert Ct values to total virus used samples from
the MOI 5 experiments.
Infections
Twenty-four-well plates were seeded with Vero C1008 cells at 105 cells/mL. EBOV was added
at MOIs of either 5, 1, or 0.1. Vero cells were grown to 90% confluence for all infections. The
cell culture medium was not changed during the experiment and all cultures reached conflu-
ence within 24 h (S1 Appendix). At pre-determined intervals post-infection samples were
taken by aspiration of supernatant from wells. Samples were stored at −80˚C prior to enumera-
tion by TCID50 assay and RNA extraction for PCR. Note that the RNA from the MOI 5 infec-
tion was omitted from further analysis due to inconsistencies in the peak viral RNA, compared
to the MOI 1 and 0.1 infections (S1 Appendix, Fig. A). The viability of Vero cells in the absence
of infection is not known under these conditions, however, we have observed these cells for
168 h at 24 h intervals and observed only occasional cells that can be stained with the viability
stain Trypan blue.
PLOS COMPUTATIONAL BIOLOGY Quantification of Ebola virus replication kinetics in vitro
PLOS Computational Biology | https://doi.org/10.1371/journal.pcbi.1008375 November 2, 2020 8 / 15
Mock yield or infectivity decay assay
EBOV was added to twenty-four-well plates at a final estimated density of 5 × 105 TCID50. At
pre-determined intervals post-infection samples were taken by aspiration of supernatant from
wells. Samples were stored at −80˚C prior to enumeration by TCID50 assay and RNA extrac-
tion for PCR.
Construction of the standard RT-qPCR curve
The concentration of viral genome copies (copy/mL) in a standard sample i (VSTD,i) and the
number of doubling RT-qPCR cycles (Ct,STD,i) required for this concentration of copies to
reach an arbitrarily fixed, chosen threshold concentration (Qt), are linked by the equation








where ε is the efficacy of the RT-qPCR doubling, which should ideally be equal to one (i.e.,
exactly doubles at each cycle) but can vary about this value. In constructing the standard
curve, we took five standard samples (VSTD,i=1. . .5) with known copy concentrations (via their
mass) and determined their corresponding Ct,STD,i. These data are shown in Fig 3.
Fig 3. Standard RT-qPCR curve. Cycle threshold values (Ct) were converted to total virus (copy/mL) using the above
calibration curve, where the parameters of the curve were estimated as a part of the analysis. The lines represent the
pointwise median bracketed by 68% (light grey) and 95% (dark grey) CR.
https://doi.org/10.1371/journal.pcbi.1008375.g003
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Conversion of sample RT-qPCR Ct values into Vtot
In quantifying the concentration of total virus, Vtot (copy/mL), in the extracellular virus sam-
ples collected from infection experiments, Eq (2) was used as follows
lnðVtot;iÞ ¼ lnðQtÞ   lnð2εÞ Ct;sample;i � FðCt;sample;iÞ ð3Þ
where Vtot,i is the concentration of copies in sample i, given its RT-qPCR-determined Ct,sample, i
value. Here, ln(Qt) and ln(2ε) are two parameters to be estimated as part of the MCMC parame-
ter estimation process described later in this section. As different values for these two parameters
are sampled in the MCMC process, the total virus concentration data points vary. The variation
in the conversion is denoted by error bars on each total virus data point in Fig 1E–1G.
Mock-yield assay model
Loss of virus infectivity or loss of viral genome integrity over time typically follows an expo-
nential decay [22]. As such, the mock-yield (MY) or infectivity decay assay can be captured via
V(t) = V0 e−ct, such that the experimental MY data are expected to follow
lnðVinfðtÞÞ ¼ lnðVMYinf;0Þ   cinf t ð4Þ
lnðVtotðtÞÞ ¼ lnðVMYtot;0Þ   ctot t ð5Þ
where Vinf(t) and Vtot(t) are the concentrations of infectious (TCID50/mL) and total (copy/
mL) virus after an incubation of time t under the same conditions used during the infection
experiments, given the EBOV rate of loss of infectivity (cinf) or integrity (ctot), and initial con-
centrations, VMYinf;0 and V
MY
tot;0. These data are shown in Fig 1D and 1G.
Simulated infections and parameter estimation
In estimating the MM parameters, the following experimental data were considered simulta-
neously: the RT-qPCR standardized curve (5 data points), the MY assays (24 data points: 4
time points in triplicate for Ct and Vinf), and three infection assays at MOI of 5 (24 data points:
6 time points in duplicate for Ct and Vinf), MOI of 1 (54 data points: 9 time points in triplicate
for Ct and Vinf), and MOI of 0.1 (53 data points: 9 time points in triplicate for Ct and Vinf,
minus one contaminated sample in Ct).
Eq (2) was used to capture the RT-qPCR standard curve, and its agreement with the 5
experimental data points was computed as the sum-of-squared residuals (SSR)
SSRSTD ¼
P5




where s2Vtot is the variance, or squared of the standard error, in experimentally measured Vtot,
which will be discussed in more details below. Eqs (4) and (5) were used to capture the MY
experiment, performed in triplicate, and sampled at 4 time points, for each of Ct and Vinf, and












tot;0Þ   ctot ti   FðCt;iÞ�
2
s2Vtot
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Finally, MM Eq (1) was used to reproduce the infection experiments, performed in tripli-
cate, and at 3 different MOIs (5, 1, and 0.1), and quantified via both TCID50 and RT-qPCR. In
reproducing the infections, initial conditions (at t = 0) were such that T(0) = 1,
Ei¼1;:::;nEð0Þ ¼ Ij¼1;:::;nI ð0Þ ¼ 0, and the initial infectious and total virus concentrations for the 3
MOIs were computed as:
Vinfð0Þ ¼ V INFinf;0 �MOI
Vtotð0Þ ¼ V INFtot;0 �MOI
where MOI was either 5, 1 or 0.1, and (V INFinf;0, V
INF
tot;0) are 2 parameters to be estimated. Agree-














tot ðtiÞ   FðCt;iÞ�
2
s2Vtot
where s2Vinf ¼ 0:1 and s
2
Vtot
¼ 0:1 correspond to the variance in ln(Vinf) and ln(Vtot), respec-
tively, estimated as the variance of the residuals between the 2 to 3 replicates of ln(Vinf) or ln
(Vtot) measured at each time point and their corresponding mean, across all (STD, MY, and
INF) experimental data collected.







tot;0) and 9 parameters more closely associated with EBOV
infection kinetics (cinf, ctot, pinf, ptot, β, τE, τI, nE, nI)—were estimated (Table 1) from 160 experi-
mental data points using the python MCMC implementation phymcmc [55], a wrapping
library for emcee [56]. Posterior probability likelihood distributions (PostPLDs) were obtained
Table 1. Estimated parameters of EBOV infection in vitro.
Parameter Mode [95% CR]
Infectiousness, β ( mLTCID50 �h) 10
−6.48 [−6.7, −6.3]
Eclipse phase length, τE (h) 30.5 [26, 37]
Number of eclipse compartments, nE 13 [8, 23]
Infectious phase length, τI (h) 83.2 [64, 95]
Number of infectious compartments, nI 14 [3, 85]
Infectious virus production rate, pinf (TCID50cell�h ) 10
1.12 [1, 1.3]
Total virus production rate, ptot (RNAcell�h) 10
6.46 [6.3, 6.7]
Rate of loss of infectious virus, cinf (/h) 0.0614 [0.055, 0.068]
Rate of virus degradation, ctot (/h) 0.00817 [0.0035, 0.013]




Initial total virus inoculum, V INFtot;0 (RNAmL ) 10
11.5 [11, 12]
MY initial infectious virus inoculum, lnðVMYinf ;0Þ 13.7 [13, 14]
MY initial total virus inoculum, lnðVMYtot;0Þ 28.2 [28, 29]
Standard RT-qPCR curve y-intercept, ln(Qt) 37.8 [37, 39]
Standard RT-qPCR curve slope, ln(2ε) 0.613 [0.57, 0.66]
Basic reproductive number, R0 102.77 [2.6, 3]
Infectious burst size, pinf τI (TCID50cell ) 10
3.04 [3, 3.1]
Infecting time, tinf (h) 100.335 [0.21, 0.43]
https://doi.org/10.1371/journal.pcbi.1008375.t001
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SSRSTDð~pÞ þ SSRMYð~pÞ þ SSRINFð~pÞ
� �
and the assumption of linearly uniform or ln-uniform priors, where~p is the 15-parameter
vector.
Supporting information
S1 Appendix. Kinetics of cell-associated virus and cell viability.
(PDF)
Acknowledgments
Members of the CL4 Virology Team include Lin Eastaugh, Lyn M. O’Brien, James S. Findlay,
Mark S. Lever, Amanda Phelps, Sarah Durley-White, Jackie Steward and Ruth Thom. The
authors would like to acknowledge Joseph Gillard for helpful discussions and the International
Centre for Mathematical Sciences (ICMS), where the mathematical model was developed dur-
ing a Research-in-Groups programme.
Author Contributions
Conceptualization: Laura E. Liao, Jonathan Carruthers, Thomas R. Laws, Carmen Molina-
Parı́s.
Data curation: Sophie J. Smither, Simon A. Weller, Diane Williamson, Thomas R. Laws, Isa-
bel Garcı́a-Dorival, Julian Hiscox.
Formal analysis: Laura E. Liao, Jonathan Carruthers, Benjamin P. Holder, Catherine A. A.
Beauchemin, John N. Barr.
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